TIPE3 and neoplasm: To explore the anti-tumor effects of the six candidate compounds mentioned above, we selected human colon cancer cell lines HT-29 and LoVo (with high TIPE3 expression), the human esophageal carcinoma cell line TE-1 (with moderate TIPE3 expression), and the human T lymphocyte cell line Jurkat (with little or no TIPE3 expression) for further experimental studies.